Why the study?
The utility of the systemic coagulation-inflammation index (SCI) in perioperative risk stratification for anti-inflammatory therapy in patients with acute type A aortic dissection (ATAAD) needed evaluation.
Does ulinastatin reduce postoperative cardiovascular dysfunction and systemic inflammatory response syndrome in patients with acute type A aortic dissection stratified by the systemic coagulation-inflammation index?
Cohort (n=339)
Does ulinastatin reduce postoperative cardiovascular dysfunction and systemic inflammatory response syndrome in patients with acute type A aortic dissection stratified by the systemic coagulation-inflammation index?
The systemic coagulation-inflammation index (SCI) may help stratify acute type A aortic dissection patients to identify high-risk individuals who derive greater benefit from ulinastatin in reducing postoperative cardiovascular dysfunction and SIRS.
Answers are grounded in this paper and cite their sources.
SCI stratification may identify ATAAD patients for ulinastatin; leaves open need for RCTs before practice change.
Purpose This study aimed to evaluate the utility of the systemic coagulation-inflammation index (SCI) in perioperative risk stratification for anti-inflammatory therapy in patients with acute type A aortic dissection (ATAAD). Methods A retrospective cohort of 339 consecutive ATAAD patients was analyzed. Patients were stratified into two groups based on the threshold of SCI index: high-risk group (SCI < 40, *n* = 233), low-risk group (SCI ≥ 40, *n* = 106). Multivariable linear regression was performed within the high-risk group to assess the independent association between ulinastatin use and postoperative cardiovascular function, adjusting for potential confounders. An interaction analysis was conducted to formally test whether the treatment effect varied by risk level. An exploratory mediation analysis was also conducted. Results The high-risk group exhibited more severe inflammation and organ dysfunction, with significantly higher rates of systemic inflammatory response syndrome (SIRS) before surgery ( *P* = 0.012), cumulative incidence of SIRS within 7 days after surgery ( *P* = 0.015), and higher mean daily total modified Sequential Organ Failure Assessment (SOFA) score (high-risk group: 6.5 [IQR 4.1–9.0]; low-risk group: 3.7 [IQR 2.7–6.0]; *P* < 0.001). While ulinastatin was associated with lower rates of SIRS in both groups ( *P* < 0.001), high-risk patients showed more pronounced and earlier differences in inflammatory and organ-dysfunction, including a lower mean daily modified SOFA score on postoperative day 1 ( *P* = 0.038) and a lower mean daily cardiovascular score ( *P* = 0.008), as well as a lower rate of SIRS immediately after surgery ( *P* = 0.005). Multivariable analysis showed that ulinastatin use was independently associated with a lower cardiovascular SOFA score in the high-risk group ( *P* < 0.001), and a significant interaction was observed between additional ulinastatin use and risk level ( *P* for interaction = 0.029). Conclusion The SCI index is a moderate predictor of adverse outcomes in ATAAD patients and may serve as a potential risk stratification tool. High-risk patients showed a more pronounced inverse association between ulinastatin use and postoperative cardiovascular dysfunction.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Acute type A aortic dissection (ATAAD) (n=339). High-risk systemic coagulation-inflammation index (SCI < 40) and ulinastatin use vs. Low-risk systemic coagulation-inflammation index (SCI ≥ 40) and no/lower ulinastatin use was evaluated on Mean daily total modified Sequential Organ Failure Assessment (SOFA) score and postoperative cardiovascular SOFA score (p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: